Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Oleandomycin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 12/20 | 0.96 |
| ▸ | LMNA | P02545 | 3/20 | 0.96 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.71 |
| ▸ | USP2 | O75604 | 2/20 | 0.71 |
| ▸ | MLNR | O43193 | 4/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.43 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ALB | P02768 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.42 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oleandomycin SCHEMBL3717 | 0.98 | CYP3A4 (1.00) | CYP3A4LMNAABCB1USP2MLNR | |
| Oleandomycin SCHEMBL10028439 | 0.98 | CYP3A4 (1.00) | CYP3A4LMNAABCB1USP2MLNR | |
| Oleandomycin SCHEMBL3716 | 0.98 | CYP3A4 (1.00) | CYP3A4LMNAABCB1USP2MLNR | |
| Oleandomycin SCHEMBL9807053 | 0.97 | CYP3A4 (0.99) | CYP3A4LMNAABCB1USP2MLNR | |
| Oleandomycin SCHEMBL285338 | 0.95 | CYP3A4 (1.00) | CYP3A4LMNAABCB1USP2MLNR | |
| Oleandomycin SCHEMBL5033021 | 0.95 | CYP3A4 (1.00) | CYP3A4LMNAABCB1USP2MLNR | |
| SCHEMBL11029029 | 0.90 | CYP3A4 (0.85) | CYP3A4LMNAABCB1USP2MLNR | |
| Diproleandomycin SCHEMBL2109038 | 0.86 | CYP3A4 (0.78) | CYP3A4LMNAABCB1USP2MLNR | |
| SCHEMBL5551907 | 0.84 | CYP3A4 (0.74) | CYP3A4LMNAABCB1USP2MLNR | |
| Troleandomycin SCHEMBL664623 | 0.83 | CYP3A4 (1.00) | CYP3A4LMNAABCB1USP2MLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027191-A1 | COMPOSITIONS AND METHODS FOR TREATING BACTERIAL DISEASE | UNIV ARIZONA (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4628100-A2 | ANTI-VIRAL COMPOUNDS AND METHODS FOR ADMINISTRATION THEREOF | Gregg, John Malcolm Hall (US) | 2025-10-08 | — | — | EP | disclosed |
| US-12285413-B2 | Anti-viral agents and methods for administration thereof | GREGG JOHN M H (US) | 2025-04-29 | — | — | US | disclosed |
| US-20250099566-A1 | COMPOSITIONS AND METHODS FOR TREATING BACTERIAL DISEASE | NATIONAL INSTITUTES OF HEALTH | 2025-03-27 | — | — | US | disclosed |
| US-20240173456-A1 | THERAPEUTIC COMPOSITIONS FOR WOUND TREATMENT | ARIZONA BOARD OF REGENTS ON BEHALF OF NORTHERN ARIZONA UNIVERSITY | 2024-05-30 | — | — | US | disclosed |
| WO-2023201345-A2 | COMPOSITIONS AND METHODS FOR TREATING BACTERIAL DISEASE | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2023-10-19 | — | — | WO | disclosed |
| US-20230263778-A1 | ANTI-VIRAL COMPOUNDS AND METHODS FOR ADMINISTRATION THEREOF | GREGG JOHN M H (US) | 2023-08-24 | — | — | US | disclosed |
| WO-2023137320-A2 | COMPOSITIONS AND METHODS FOR TREATING BACTERIAL DISEASE | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2023-07-20 | — | — | WO | disclosed |
| US-20230201167-A1 | ANTI-VIRAL AGENTS AND METHODS FOR ADMINISTRATION THEREOF | GREGG JOHN M H (US) | 2023-06-29 | — | — | US | disclosed |
| EP-4110330-A1 | ANTI-VIRAL COMPOUNDS AND METHODS FOR ADMINISTRATION THEREOF | Gregg, John Malcolm Hall (US) | 2023-01-04 | — | — | EP | disclosed |
| EP-2346516-A2 | ANTIMICROBIAL COMPOSITION FROM COPEPODS | Nofima Ingrediens (NO) | 2011-07-27 | — | — | EP | disclosed |
| US-20110021964-A1 | Device for Promotion of Hemostasis and/or Wound Healing | Ferrosan Medical Devices A/S (DK) | 2011-01-27 | — | — | US | disclosed |
| EP-2259803-A2 | DEVICE FOR PROMOTION OF HEMOSTASIS AND/OR WOUND HEALING | Ferrosan Medical Devices A/S (DK) | 2010-12-15 | — | — | EP | disclosed |
| WO-2010049454-A2 | ANTIMICROBIAL COMPOSITION FROM COPEPODS | NOFIMA INGREDIENS (NO) | 2010-05-06 | — | — | WO | disclosed |
| WO-2010009735-A2 | COMBINATORIAL ANALYSIS AND REPAIR | DAKO DENMARK A/S (DK) | 2010-01-28 | — | — | WO | disclosed |
| WO-2009109194-A2 | DEVICE FOR PROMOTION OF HEMOSTASIS AND/OR WOUND HEALING | FERROSAN A/S (DK) | 2009-09-11 | — | — | WO | disclosed |
| EP-1904041-A2 | NANOPARTICULATE CLARITHROMYCIN FORMULATIONS | Elan Pharma International Limited (IE) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007008537-A2 | NANOPARTICULATE CLARITHROMYCIN FORMULATIONS | ELAN PHARMA INTERNATIONAL, LIMITED (IE) | 2007-01-18 | — | — | WO | disclosed |
| US-20070015719-A1 | Nanoparticulate clarithromycin formulations | ELAN PHARMA INTERNATIONAL LIMITED | 2007-01-18 | — | — | US | disclosed |
| WO-2001092288-A2 | COBALAMIN COMPOUNDS USEFUL AS ANTIBIOTIC AGENTS AND AS IMAGING AGENTS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230263778-A1 | ANTI-VIRAL COMPOUNDS AND METHODS FOR ADMINISTRATION THEREOF | ACE2, ACE, SARS1 | CYP3A4 741/4885LMNA 1742/4885ABCB1 172/4885 |
| US-20070015719-A1 | Nanoparticulate clarithromycin formulations | NPC1, NPC1L1, HDAC6 | CYP3A4 27/4885LMNA 3568/4885ABCB1 16/4885 |
| US-20260027191-A1 | COMPOSITIONS AND METHODS FOR TREATING BACTERIAL DISEASE | DNMT3L, DNMT3A, DNMT1 | CYP3A4 3633/4885LMNA 1451/4885ABCB1 375/4885 |
| US-12285413-B2 | Anti-viral agents and methods for administration thereof | ACE2, ACE, MAVS | CYP3A4 754/4885LMNA 2369/4885ABCB1 253/4885 |
| US-20230201167-A1 | ANTI-VIRAL AGENTS AND METHODS FOR ADMINISTRATION THEREOF | ACE2, ACE, MAVS | CYP3A4 754/4885LMNA 2369/4885ABCB1 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.